Target Name: TENT2
NCBI ID: G167153
Other Name(s): hGLD-2 | PAPD4 | GLD-2 | TUT2 | GLD2_HUMAN | PAP-associated domain-containing protein 4 | Poly(A) RNA polymerase GLD2 | TUTase 2 | TENT2 variant 1 | Terminal uridylyltransferase 2 | Poly(A) RNA polymerase GLD2 (isoform 1) | Terminal nucleotidyltransferase 2 | poly(A) RNA polymerase D4, non-canonical | poly(A) RNA polymerase GLD2 | GLD2 | terminal nucleotidyltransferase 2 | PAP associated domain containing 4 | terminal uridylyltransferase 2 | Terminal nucleotidyltransferase 2, transcript variant 1 | APD4

TENT2: A Potential Drug Target and Biomarker

TENT2, also known as TENT2-R1, is a protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a member of the TENT family of proteins, which are known for their role in intracellular signaling. Several studies have identified TENT2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The TENT2 protein is composed of 214 amino acid residues and has a calculated pI of 9.95 nM. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is involved in intracellular signaling pathways. One of the most well-studied functions of TENT2 is its role in the regulation of mitochondrial function and energy metabolism. TENT2 has been shown to interact with various cellular components, including the mitochondrial protein complex IKAP, which is involved in the transfer of electrons during mitochondrial function.

In addition to its role in intracellular signaling, TENT2 has also been shown to play a role in the regulation of inflammation and immune responses. It has been shown to interact with various immune cell types, including T cells and macrophages, and has been shown to play a role in the regulation of inflammation-related processes.

As a potential drug target, TENT2 has been studied for its potential effects on various diseases. Several studies have shown that TENT2 may be a useful target for cancer, neurodegenerative diseases, and cardiovascular diseases.

In the context of cancer, TENT2 has been shown to play a role in the regulation of cell proliferation and survival. Several studies have shown that TENT2 levels are elevated in various types of cancer, including breast cancer, lung cancer, and colon cancer. Additionally, TENT2 has been shown to interact with various oncogenic signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cancer cell growth and survival.

In the context of neurodegenerative diseases, TENT2 has been shown to play a role in the regulation of neurotransmitter signaling and synaptic plasticity. Several studies have shown that TENT2 levels are elevated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, TENT2 has been shown to interact with various neurotransmitter receptors, including dopamine, which is involved in the regulation of mood, motivation, and reward.

In the context of cardiovascular diseases, TENT2 has been shown to play a role in the regulation of vascular function and inflammation. Several studies have shown that TENT2 levels are elevated in various cardiovascular diseases, including heart failure, hypertension, and diabetes. Additionally, TENT2 has been shown to interact with various signaling pathways, including the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation and immune responses.

Overall, TENT2 is a protein that has been shown to play a role in a variety of biological processes, including intracellular signaling, inflammation, and immune responses. As a potential drug target, TENT2 has the potential to be used for the treatment of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Further research is needed to fully understand the role of TENT2 in these processes and to develop safe and effective treatments.

Protein Name: Terminal Nucleotidyltransferase 2

Functions: Cytoplasmic poly(A) RNA polymerase that adds successive AMP monomers to the 3'-end of specific RNAs, forming a poly(A) tail. In contrast to the canonical nuclear poly(A) RNA polymerase, it only adds poly(A) to selected cytoplasmic mRNAs (PubMed:15070731). Does not play a role in replication-dependent histone mRNA degradation (PubMed:18172165). Adds a single nucleotide to the 3' end of specific miRNAs, monoadenylation stabilizes and prolongs the activity of some but not all miRNAs (PubMed:23200856)

More Common Targets

TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI